440 related articles for article (PubMed ID: 25217640)
1. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
Tai LM; Koster KP; Luo J; Lee SH; Wang YT; Collins NC; Ben Aissa M; Thatcher GRJ; LaDu MJ
J Biol Chem; 2014 Oct; 289(44):30538-30555. PubMed ID: 25217640
[TBL] [Abstract][Full Text] [Related]
2. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
Boehm-Cagan A; Michaelson DM
J Neurosci; 2014 May; 34(21):7293-301. PubMed ID: 24849361
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.
Zhao J; Fu Y; Liu CC; Shinohara M; Nielsen HM; Dong Q; Kanekiyo T; Bu G
J Biol Chem; 2014 Apr; 289(16):11282-11292. PubMed ID: 24599963
[TBL] [Abstract][Full Text] [Related]
4. A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.
Valencia-Olvera AC; Balu D; Bellur S; McNally T; Saleh Y; Pham D; Ghura S; York J; Johansson JO; LaDu MJ; Tai L
Alzheimers Res Ther; 2023 Dec; 15(1):216. PubMed ID: 38102668
[TBL] [Abstract][Full Text] [Related]
5. Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1.
Tachibana M; Shinohara M; Yamazaki Y; Liu CC; Rogers J; Bu G; Kanekiyo T
Exp Neurol; 2016 Mar; 277():1-9. PubMed ID: 26688581
[TBL] [Abstract][Full Text] [Related]
6. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Corona AW; Kodoma N; Casali BT; Landreth GE
J Neuroimmune Pharmacol; 2016 Mar; 11(1):61-72. PubMed ID: 26175148
[TBL] [Abstract][Full Text] [Related]
7. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.
Youmans KL; Tai LM; Nwabuisi-Heath E; Jungbauer L; Kanekiyo T; Gan M; Kim J; Eimer WA; Estus S; Rebeck GW; Weeber EJ; Bu G; Yu C; Ladu MJ
J Biol Chem; 2012 Dec; 287(50):41774-86. PubMed ID: 23060451
[TBL] [Abstract][Full Text] [Related]
8. APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice.
Liu DS; Pan XD; Zhang J; Shen H; Collins NC; Cole AM; Koster KP; Ben Aissa M; Dai XM; Zhou M; Tai LM; Zhu YG; LaDu M; Chen XC
Mol Neurodegener; 2015 Mar; 10():7. PubMed ID: 25871877
[TBL] [Abstract][Full Text] [Related]
9. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
Fanaee-Danesh E; Gali CC; Tadic J; Zandl-Lang M; Carmen Kober A; Agujetas VR; de Dios C; Tam-Amersdorfer C; Stracke A; Albrecher NM; Manavalan APC; Reiter M; Sun Y; Colell A; Madeo F; Malle E; Panzenboeck U
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2224-2245. PubMed ID: 31055081
[TBL] [Abstract][Full Text] [Related]
10. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.
Tai LM; Bilousova T; Jungbauer L; Roeske SK; Youmans KL; Yu C; Poon WW; Cornwell LB; Miller CA; Vinters HV; Van Eldik LJ; Fardo DW; Estus S; Bu G; Gylys KH; Ladu MJ
J Biol Chem; 2013 Feb; 288(8):5914-26. PubMed ID: 23293020
[TBL] [Abstract][Full Text] [Related]
11. A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice.
Balu D; Valencia-Olvera AC; Nguyen A; Patnam M; York J; Peri F; Neumann F; LaDu MJ; Tai LM
Alzheimers Res Ther; 2023 Oct; 15(1):181. PubMed ID: 37858252
[TBL] [Abstract][Full Text] [Related]
12. Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.
Rodriguez GA; Tai LM; LaDu MJ; Rebeck GW
J Neuroinflammation; 2014 Jun; 11():111. PubMed ID: 24948358
[TBL] [Abstract][Full Text] [Related]
13. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.
Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM
Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice.
Carter AY; Letronne F; Fitz NF; Mounier A; Wolfe CM; Nam KN; Reeves VL; Kamboh H; Lefterov I; Koldamova R
PLoS One; 2017; 12(2):e0172161. PubMed ID: 28241068
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.
Wahrle SE; Jiang H; Parsadanian M; Kim J; Li A; Knoten A; Jain S; Hirsch-Reinshagen V; Wellington CL; Bales KR; Paul SM; Holtzman DM
J Clin Invest; 2008 Feb; 118(2):671-82. PubMed ID: 18202749
[TBL] [Abstract][Full Text] [Related]
16. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.
Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R
J Neurosci; 2012 Sep; 32(38):13125-36. PubMed ID: 22993429
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease.
Wahrle SE; Jiang H; Parsadanian M; Hartman RE; Bales KR; Paul SM; Holtzman DM
J Biol Chem; 2005 Dec; 280(52):43236-42. PubMed ID: 16207708
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
Cummings JL; Zhong K; Kinney JW; Heaney C; Moll-Tudla J; Joshi A; Pontecorvo M; Devous M; Tang A; Bena J
Alzheimers Res Ther; 2016 Jan; 8():4. PubMed ID: 26822146
[TBL] [Abstract][Full Text] [Related]
19. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
[TBL] [Abstract][Full Text] [Related]
20. APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease.
Lin AL; Parikh I; Yanckello LM; White RS; Hartz AMS; Taylor CE; McCulloch SD; Thalman SW; Xia M; McCarty K; Ubele M; Head E; Hyder F; Sanganahalli BG
Neurobiol Dis; 2020 Jun; 139():104834. PubMed ID: 32173556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
